Last reviewed · How we verify

Aspirin — Competitive Intelligence Brief

Aspirin (acetylsalicylic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID, Antiplatelet agent.

marketed NSAID, Antiplatelet agent Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3 Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin (acetylsalicylic acid) — Bayer AG. Irreversibly inhibits cyclooxygenase-1 and -2 (COX-1/COX-2), blocking prostaglandin and thromboxane synthesis to reduce pain, inflammation, fever, and platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aspirin TARGET acetylsalicylic acid Bayer AG marketed NSAID, Antiplatelet agent Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3 1899-03-06

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID, Antiplatelet agent class)

  1. Bayer AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: